The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced systemic mastocytosis

Mathias Schneeweiss,1,2 Barbara Peter,1,2 Siham Bibi,3 Gregor Eisenwort,1,2 Dubravka Smiljkovic,4 Katharina Blatt,1,2 Mohamad Jawhar,5 Daniela Berger,2 Gabriele Stefanzl,2 Susanne Herndrhofer,1,2 Georg Greiner,6 Gregor Hoermann,7 Emir Hadzijusufovic,1,2,6 Karoline V. Gleixner,1,2 Peter Bettelheim,1,7 Klaus Geissler,8 Wolfgang R. Sperr,1,2 Andreas Reiter,1,8 Michel Arock,3 and Peter Valent1,2

1Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria; 2Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria; 3Laboratoire de Biologie et Pharmacologie Appliquee, CNRS UMR 8113, Ecole Normale Superieure de Cachan, France; 4Department of Hematology and Oncology, University Medical Centre Mannheim and Medical Faculty Mannheim, Heidelberg University, Germany; 5Department of Laboratory Medicine, Medical University of Vienna, Austria; 6Department for Companion Animals and Horses, University Clinic for Small Animals, Internal Medicine Small Animals, University of Veterinary Medicine Vienna, Austria; 7Elisabethinen Hospital Linz, Austria and 8Fifth Medical Department, Hospital Hietzing, Vienna, Austria

ABSTRACT

Systemic mastocytosis is a complex disease defined by abnormal growth and accumulation of neoplastic mast cells in various organs. Most patients exhibit a D816V-mutated variant of KIT, which confers resistance against imatinib. Clinical problems in systemic mastocytosis arise from mediator-related symptoms and/or organ destruction caused by malignant expansion of neoplastic mast cells and/or other myeloid cells in various organ systems. DCC-2618 is a spectrum-selective pan KIT and PDGFRA inhibitor which blocks KIT D816V and multiple other kinase targets relevant to systemic mastocytosis. We found that DCC-2618 inhibits the proliferation and survival of various human mast cell lines (HMC-1, ROSA, MCPV-1) as well as primary neoplastic mast cells obtained from patients with advanced systemic mastocytosis (IC50 <1 μM). Moreover, DCC-2618 decreased growth and survival of primary neoplastic eosinophils obtained from patients with systemic mastocytosis or eosinophilic leukemia, leukemic monocytes obtained from patients with chronic myelomonocytic leukemia with or without concomitant systemic mastocytosis, and blast cells obtained from patients with acute myeloid leukemia. Furthermore, DCC-2618 was found to suppress the proliferation of endothelial cells, suggesting additional drug effects on systemic mastocytosis-related angiogenesis. Finally, DCC-2618 was found to downregulate IgE-mediated histamine release from basophils and tryptase release from mast cells. Together, DCC-2618 inhibits growth, survival and activation of multiple cell types relevant to advanced systemic mastocytosis. Whether DCC-2618 is effective in vivo in patients with advanced systemic mastocytosis is currently under investigation in clinical trials.

Introduction

Systemic mastocytosis (SM) is a hematopoietic neoplasm with complex biology and pathology, and a variable clinical course.1,7 The disease is characterized by abnormal expansion and accumulation of neoplastic mast cells (MC) in one or more...
internal organs, including the bone marrow. Various types of SM have been recognized by the World Health Organization (WHO). The indolent variant of SM is associated with ‘hematologic stability’ and thus with an almost normal life expectancy. By contrast, the prognosis in patients with advanced SM, including SM with an associated hematologic neoplasm (AHN), aggressive SM (ASM) and MC leukemia (MCL) is unfavorable, with short survival times and poor responses to conventional therapy. Current research is, therefore, focusing on therapeutic targets and the effects of novel antineoplastic drugs on various cell types relevant to advanced SM. Since most patients with SM also suffer from mediator-related symptoms that may sometimes be severe or even life-threatening, such drugs are often selected based on their dual effects on MC growth and MC activation.

Most patients with SM express the D816V-mutated variant of the stem cell factor receptor, KIT, which mediates ligand-independent activation and autonomous growth and differentiation of MC. The D816V KIT point mutation also confers resistance against several tyrosine kinase inhibitors, including imatinib. Novel kinase blockers acting on KIT D816V have, therefore, been developed. The highlighting example is midostaurin (PKC412). However, despite superior clinical efficacy seen in a global phase II trial, patients with advanced SM often exhibit or acquire resistance. A number of different mechanisms may underlie resistance against midostaurin. One obvious problem is that the drug does not suppress all clinically relevant sub-clones and cell-types, especially cells lacking KIT D816V. Such sub-clones are often seen in the context of advanced SM. Over 50% of these patients have or develop an AHN. Of these patients with an AHN, approximately 80-90% have an associated myeloid neoplasm, the most frequent ones being chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). In these patients, leukemic expansion of monocytes and/or blast cells is typically found. In other patients, an expansion of eosinophils, sometimes resembling chronic eosinophilic leukemia (SM-CEL), is found. In most of these patients, eosinophils display KIT D816V. By contrast, expression of rearranged PDGFR variants is rarely seen in SM, although in some patients with a FIP1L1/PDGFRα fusion gene, the MC expansion has a histopathological picture indistinguishable from that of SM. Treatment of SM-AHN represents a clinical challenge because the AHN-component is often resistant. DCC-2618 is a switch-control type II inhibitor of KIT, which arrests KIT in an inactive state, regardless of activating mutations, such as KIT D816V. Moreover, several additional oncogenic kinases, including FLT-3, PDGFRα, PDGFRβ, KDR, TIE2 and FMS are recognized by DCC-2618. Recently, the first clinical trials with DCC-2618 (NCT02571056) were started in patients with kinase-driven malignancies. In addition, first preclinical studies have shown that DCC-2618 may exert antineoplastic effects on neoplastic MC.

In our current study, we show that DCC-2618 is a potent inhibitor of growth and survival of neoplastic human MC expressing various KIT mutations. Furthermore, we show that DCC-2618 produces growth inhibition and apoptosis in other cell types that play a role in advanced SM. Finally, we show that DCC-2618 inhibits IgE-dependent histamine secretion from basophils and tryptase secretion from MC. All in all, our data suggest that DCC-2618 is a promising, novel drug for the treatment of advanced SM.

Methods

Reagents

The reagents used in this study are described in the Online Supplement. DCC-2618 and its active metabolite, DP-5439, were kindly provided by Dr. B. Smith (Deciphera Pharmaceuticals LLC, Lawrence, KS, USA).

Isolation of primary neoplastic cells

Primary neoplastic cells were isolated from bone marrow samples of 11 patients with SM. The bone marrow cells were obtained during routine diagnostic investigations after written

Table 1. Characteristics of patients with systemic mastocytosis and response of neoplastic cells to DCC-2618 and DP-5439.

| Patient n. | Age | m/f | Diagnosis, SM variant | KIT D816V | Serum tryptase ng/mL | BM MC infiltration % | % MC in MNC | DCC-2618 IC50 nM | DP-5439 IC50 nM | PKC412 IC50 nM |
|------------|-----|-----|------------------------|-----------|---------------------|----------------------|------------|-----------------|----------------|----------------|
| #1         | 68  | m   | ISM                    | +         | 83.3                | n.a.                 | 1          | 114             | 414            | 56             |
| #2         | 56  | m   | ISM                    | +         | 103                 | 20                   | 5          | 240             | 390            | 35             |
| #3         | 49  | f   | ISM                    | -         | 22.9                | 10                   | n.a.       | 198             | 554            | n.a.           |
| #4         | 66  | m   | ISM-MPN-eo             | +         | 170                 | 5                    | n.a.       | 394             | 1481           | n.a.           |
| #5         | 82  | f   | SSM                    | +         | 284                 | 50                   | n.a.       | 347             | 1584           | n.a.           |
| #6         | 57  | f   | ASM                    | +         | 87.9                | 50                   | n.a.       | 331             | 366            | n.a.           |
| #7         | 90  | m   | ASM                    | +         | 125                 | 20                   | 25         | 386             | 679            | 360            |
| #8         | 63  | m   | ASM-AML                | +         | 33.9                | 15                   | 8          | 383             | 554            | 66             |
| #9         | 65  | m   | ASM-CMML               | +         | 220                 | 50                   | 30         | 460             | 907            | n.a.           |
| #10        | 78  | m   | ASM-MPN-eo             | +         | 45.9                | 15                   | 5          | 83              | 64             | 114            |
| #11        | 91  | m   | MCL                    | +         | 330                 | 20                   | 50         | 321             | 592            | 65             |

Diagnoses were established according to WHO criteria. Primary bone marrow cells were incubated with various concentrations of DCC-2618, DP-5439 or midostaurin (PKC412) at 37°C for 48 h. Proliferation was then determined by measuring uptake of [3H]thymidine and IC50 values were calculated WHO World Health Organization; m: male; f: female; SM: systemic mastocytosis; PB: peripheral blood; BM: bone marrow; MC: mast cells; MNC: mononuclear cells; nM: nanomolar; n.a.: not available; IC50: half maximal inhibitory concentration; SM: SM: indolent SM; MPN: myeloproliferative neoplasm; SSM: smoldering SM; ASM: aggressive SM; CMML: chronic myelomonocytic leukemia; MCL: mast cell leukemia.
informed consent had been given. Patients were classified as having indolent SM (ISM; n=5), smoldering SM (SSM; n=1), ASM (n=2), SM-AHN (n=4) and MCL (n=1) according to WHO criteria. In addition, neoplastic cells were obtained from ten patients suffering from CML, ten with AML and three with hypereosinophilia. The patients’ characteristics are shown in Table 1 (SM patients) and Online Supplementary Table S1 (other hematologic disorders). Heparinized bone marrow cells were layered over Ficoll to isolate mononuclear cells. The study was approved by the ethics committee of the Medical University of Vienna.

Culture of human cell lines
The following human MCL-like cell lines were employed in this study: HMC-1.1 and HMC-1.2, three ROSA sub-clones (ROSA WT, ROSA D816V, ROSA KIT WT, ROSA KIT D816V) and four MCPV-1 subclones (MCPV-1.1, MCPV-1.2, MCPV-1.3, MCPV-1.4). In addition, we examined several AML cell lines, the CEL-related cell line EOL-1, the microvascular endothelial cell line HMEC-1, and cultured human umbilical vein endothelial cells (HUVEC). A description of cell lines is provided in the Online Supplement.

Evaluation of growth, survival of neoplastic cells
Drug-exposed cells (cell lines or primary cells) were analyzed for proliferation and survival. The biosassays employed are described in the Online Supplementary Methods.

Western blotting
For evaluation of KIT and BTK signaling, HMC-1.1, HMC-1.2, ROSA WT and ROSA D816V cells were incubated in control medium or in DCC-2618 (0.5-5 μM) for 4 h at 37°C. Western blotting was performed essentially as described elsewhere. For evaluation of downstream signaling pathways of KIT, HMC-1.1, HMC-1.2, ROSA WT and ROSA D816V cells were first preincubated overnight in Iscove modified Dulbecco medium devoid of fetal calf serum and of stem cell factor. Cells (10⁷) from each line were then treated with DCC-2618 (0.001-10 μM) for 90 min at 37°C. At the end of the treatment, ROSA WT cells were stimulated with stem cell factor-containing supernatants (10%) of Chinese hamster ovary cells transfected with the murine scf (kl) gene (CHO-KL) at room temperature for 10 min. Thereafter, Western blotting was performed essentially as described previously. Antibodies against phosphorylated (p)Kit, STAT5, pSTAT5, ERK1/2, pERK1/2 were purchased from Cell Signaling (Danvers, MA, USA), antibodies against pBTK were bought from NovusBiologics (Littleton, CO, USA) and antibodies against total KIT and total BTK were from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Measurement of mediator release
Drug-exposed cells (blood basophils obtained from healthy individuals and HMC-1 cells) were analyzed for histamine- and tryptase release as described in the Online Supplementary Methods.

Evaluation of apoptosis in basophils
Drug-exposed blood basophils obtained from healthy donors by dextran sedimentation were analyzed for cell survival by tryptase release as described in the Online Supplementary Methods.

Statistical analysis
To determine the level of significance the Student t-test was applied. Results were considered to be statistically significantly different when P was <0.05.

Results

DCC-2618 and its metabolite DP-5439 inhibit proliferation of neoplastic mast cells
DCC-2618 and its active metabolite, DP-5439 were found to inhibit ‘H-thymidine uptake and thus proliferation in a dose-dependent manner in all MC lines tested, with slightly lower IC₅₀ values obtained in HMC-1 cells lacking KIT D816V and ROSA KIT WT cells compared to the KIT D816V-positive cell lines HMC-1.2 and ROSA KIT D816V (Figure 1A and Table 2). IC₅₀ values obtained in HMC-1 cells with DCC-2618 were also lower than IC₅₀ values obtained with midostaurin. In addition, DCC-2618 and DP-5439 were found to inhibit proliferation of ROSA KIT D816V cells with lower IC₅₀ values (DCC-2618, IC₅₀: 34±10 nM) compared to ROSA KIT D816V cells (Figure 1A). Unexpectedly, DCC-2618 and its metabolite also produced growth-inhibition in the multi-resistant MC lines MCPV-1.1, MCPV-1.2, MCPV-1.3 and MCPV-1.4 (Figure 1B and Table 2). Finally, we were able to show that DCC-2618 and DP-5439 induced dose-dependent inhibition of growth of primary neoplastic bone marrow cells obtained from patients suffering from various forms of SM, including ASM and MCL (Figure 1C, Table 1). Interestingly, the effects of DCC-2618 on primary neoplastic BM cells and the related IC₅₀ values obtained in different SM variants were comparable (Figure 1C, Table 1).

DCC-2618 inhibits KIT, STAT5, AKT, and ERK activation in neoplastic mast cells
As expected, DCC-2618 was found to suppress phosphorylation of KIT in ROSA WT and ROSA D816V cells as well as in both HMC-1 sub-clones (Figure 2A). In addition, DCC-2618 was found to decrease the expression of phosphorylated (p)STAT5, pAKT and pERK1/2 in all cell lines tested (Figure 2B). As expression levels of pSTAT5 in Table 2. Effects of DCC-2618 and DP-5439 on growth of various human cell types.

| Cell line / cell type | DCC-2618, IC₅₀ | DP-5439, IC₅₀ |
|----------------------|----------------|---------------|
| HMC-1.1              | 12.3±3.7 nM    | 13±4 nM       |
| HMC-1.2              | 123±36 nM      | 96±23 nM      |
| ROSA KIT WT          | 41±5 nM        | 56±21 nM      |
| ROSA KIT D816V       | 168±65 nM      | 188±60 nM     |
| ROSA KIT K509I       | 34±10 nM       | 28±13 nM      |
| MCPV-1.1             | 298±77 nM      | 357±179 nM    |
| MCPV-1.2             | 1000±932 nM    | 913±578 nM    |
| MCPV-1.3             | 724±511 nM     | 756±435 nM    |
| MCPV-1.4             | 670±418 nM     | 697±410 nM    |
| MOLM-13              | 132±95 nM      | 73±31 nM      |
| MV4-11               | 147±88 nM      | 76±24 nM      |
| KG-1                 | 2.7±3.7 μM     | 5.2±4.4 μM    |
| U937                 | 7.8±5.4 μM     | 2.5±0.3 μM    |
| EOL-1                | 1.8±1.3 μM     | 1±0.8 μM      |
| HMEC-1               | 3.7±2.2 μM     | 2±1.3 μM      |
| HUVEC                | 707±224 nM     | 605±222 nM    |

Cell lines were incubated with various concentrations of DCC-2618 or DP-5439 at 37°C for 48 h. Then, proliferation was determined by measuring uptake of ‘H-thymidine and IC₅₀ values were calculated. Values represent the mean±SD from three independent experiments. IC₅₀, half maximal inhibitory concentration.
HMC-1.1 cells were rather low and difficult to quantify by Western blotting, we also performed intracellular flow cytometry-staining experiments using an antibody against pSTAT5. In these experiments, DCC-2618 was found to counteract pSTAT5 expression in HMC-1.1 and HMC-1.2 cells in a dose-dependent manner (Online Supplementary Figure S1). DCC-2618 did not inhibit phosphorylation of BTK, another important target of tyrosine kinase inhibitors expressed by neoplastic MC (Figure 2C).

**DCC-2618 induces apoptosis in neoplastic mast cells**

To explore the mechanism of drug action, we analyzed the effects of DCC-2618 on the survival of neoplastic MC. As assessed by light microscopy, DCC-2618 induced apoptosis in HMC-1.1, HMC-1.2, ROSA\(^{KIT\ WT}\), ROSA\(^{KIT\ D816V}\) and ROSA\(^{KIT\ K509I}\) cells in a dose-dependent manner (Figure 3A). The effects of DCC-2618 on survival were more pronounced in KIT D816V-negative MC lines than in KIT D816V-positive MC lines (Figure 3A). DCC-2618 was also found to produce apoptosis in the multi-resistant MCPV-1 cell lines (Figure 3B). The apoptosis-inducing effect of DCC-2618 on MC was confirmed by combined annexin V/propidium-iodide staining (Figure 3A, B and Online Supplementary Figure S2A, B). The metabolite DP-5439 was found to be equally effective in producing apoptosis in MC lines compared to DCC-2618 (Figure 3A, B and Online Supplementary Figure S2A, B). Together, these data show that DCC-2618 is a novel potent anti-neoplastic compound inducing apoptosis and growth arrest in neoplastic MC.

**DCC-2618 produces synergistic growth-inhibitory effects with midostaurin and cladribine (2CdA) in neoplastic mast cells**

In advanced SM, drug combinations may be required to suppress malignant cell growth. We found that DCC-2618 and midostaurin produce clear cooperative (synergistic) growth-inhibitory effects in HMC-1.1 cells (Online Supplementary Figure S3A, C). In HMC-1.2 cells, the drug combination also produced cooperative antineoplastic effects, but these effects were additive rather than synergistic as defined by CalcuSyn software (Online Supplementary Figure S3A, C). In addition, we found that DCC-2618 and 2CdA induce clear synergistic growth-inhibitory effects on HMC-1.1 and HMC-1.2 cells (Online Supplementary Figure S3B, D).

**Figures 1. DCC-2618 and its active metabolite DP-5439 inhibit proliferation of neoplastic mast cells.** HMC-1, ROSA (A), MCPV-1 (B) and primary neoplastic mast cells (C) obtained from patients with different variants of systemic mastocytosis (ISM, SSM, ASM, MCL) were incubated in control medium (0 nM) or medium containing various concentrations of DCC-2618 or DP-5439, as indicated, at 37°C for 48 h. Thereafter, \(^3\)H-thymidine uptake was measured. Results in (A) and (B) are expressed as percent of control and represent the mean±S.D. from three independent experiments. Results in (C) are expressed as percent of control and represent mean±S.D from triplicates. Asterisk (*) : \(P<0.05\) compared to control medium.
DCC-2618 inhibits IgE-dependent histamine release from basophils and spontaneous tryptase release from neoplastic mast cells

Since patients with SM often suffer from symptoms caused by mediators released from neoplastic MC and/or basophils, we evaluated the effect of DCC-2618 on anti-IgE-induced histamine release. We found that DCC-2618 (0.1-1.0 μM) slightly inhibited anti-IgE mediated histamine release from normal human blood basophils (Figure 4A). This drug effect was found to be specific in that DCC-2618 did not inhibit C5a- or calcium ionophore-induced histamine release from basophils (Online Supplementary Figure S4A). As expected, DCC-2618 did not affect the viability of basophils between 0.1 and 1.0 μM and did not induce histamine secretion within 30 min of incubation (Online Supplementary Figure S4B). In consecutive experiments, we also found that DCC-2618 suppresses the spontaneous (baseline) secretion of tryptase from HMC-1.1 and HMC-1.2 cells during the entire incubation period (days 1 through 6) (Figure 4B).

DCC-2618 counteracts growth and survival of leukemic monocytes and blast cells

We next explored the effects of DCC-2618 on AHN cell types. In a first step, we examined AML cell responses. DCC-2618 was found to inhibit the proliferation of all AML cell lines tested, with considerably lower IC50 values obtained with the FLT3-mutated cell lines MOLM-13 (132±95 nM) and MV4-11 (147±88 nM) compared to KG-1 and U937 cells (Table 2, Figure 5A). Similar effects were seen with DP-5439 (Figure 5A). DCC-2618 was also found to induce apoptosis in MOLM-13, MV4-11 and KG-1 cells (Figure 5B and Online Supplementary Figure S5). Finally, we found that DCC-2618 and DP-5439 produced dose-dependent inhibition of growth in primary leukemia cells obtained from patients with AML or CMML (Online Supplementary Table S1 and Figure 5C). In one patient with ASM-CMML, we isolated mononuclear cells and found that DCC-2618 and DP-5439 produced growth inhibition of these cells in the same way as in mononuclear cells obtained from patients with CMML without SM (Table 1).

Figures 2. DCC-2618 inhibits phosphorylation of KIT and other targets in neoplastic mast cells. (A,C) HMC-1 and ROSA cells were incubated in control medium (ROSАKIT WT: Iscove modified Dulbecco medium (IMDM) with stem cell factor, SCF; ROSАKIT D816V: IMDM without SCF) or medium containing various concentrations of DCC-2618, as indicated, at 37 °C for 4 h. Thereafter, cells were harvested and Western blotting was performed as described in the text using antibodies against phosphorylated (p)KIT, total KIT, pBTK and total BTK. (B) HMC-1 and ROSA cells were pre-incubated overnight in IMDM devoid of fetal calf serum and of SCF. Cells were then treated with DCC-2618 (0.001-10 μM) for 90 min at 37 °C. At the end of the treatment, ROSАKIT WT cells were stimulated with SCF (10% CHO-K1) at room temperature for 10 min. Thereafter, cells were harvested and Western blotting was performed as described in the text using antibodies against pSTAT5, total STAT5, pAKT, total AKT, pERK1/2, total ERK1/2. Western blot experiments were performed at least twice. Western blots in this figure show one representative experiment.
and Figure 5C). Together, these data suggest that DCC-2618 counteracts growth of AHN cells, including CMML monocytes and AML blasts.

**DCC-2618 inhibits the proliferation of neoplastic eosinophils**

Advanced SM is often accompanied by eosinophilia. In addition, PDGFRA is a known target of DCC-2618. We analyzed the effects of DCC-2618 on proliferation and survival of the FIP1L1-PDGFRα (F/P) positive EOL-1 cell line. DCC-2618 was found to inhibit proliferation in EOL-1 cells at low nanomolar range of concentrations (IC₅₀: 1.8±1.3 nM) ([Online Supplementary Figure S6A](#)). Similar effects were seen with DP-5439 ([Online Supplementary Figure S6A](#)). DCC-2618 also induced apoptosis in EOL-1 cells ([Online Supplementary Figure S6C](#)).

Next, we examined the effects of DCC-2618 on growth of primary eosinophils. In these experiments, DCC-2618...
was found to inhibit the proliferation of neoplastic bone marrow cells obtained from a patient with ASM (Table 1 and Online Supplementary Figure S6B). In addition, DCC-2618 was found to block the growth of bone marrow cells obtained from patients with secondary hypereosinophilic syndromes (Online Supplementary Table S4 and Online Supplementary Figure S6B).

**DCC-2618 inhibits growth of human endothelial cells**

Increased bone marrow angiogenesis has been implicated in the pathogenesis of SM. To investigate potential effects of DCC-2618 on angiogenesis, we explored drug effects on growth of HUVEC and the microvascular endothelial cell line HMEC-1. As assessed by 3H-thymidine uptake, DCC-2618 and its metabolite were found to inhibit the proliferation of HUVEC and HMEC-1 cells in a dose-dependent manner (Online Supplementary Figure S7). DCC-2618 exerted stronger effects on HUVEC (707±224 nM) than on HMEC-1 cells (3.7±2.2 µM).

**Discussion**

Due to the poor response to conventional drugs, treatment of patients with advanced SM is still a major challenge in clinical practice. Despite the availability of new drugs the prognosis of these patients remains poor with short survival times. Research is, therefore, seeking new effective drugs and novel treatment concepts. DCC-2618 is a novel switch-control type II blocker that exerts inhibitory effects on KIT D816V, other KIT mutants, and several other critical target kinases, such as FLT3, PDGFRA and KDR. We here describe that DCC-2618 inhibits the proliferation of nine different human MC lines, with lower IC50 values obtained in HMC-1.1 cells and ROSA KIT WT cells than in KIT D816V-positive HMC-1.2 and ROSA KIT D816V cells. In addition, DCC-2618 was found to block the proliferation of primary neoplastic MC obtained from patients with ASM or MCL. Moreover, DCC-2618 exerted major antineoplastic effects on AHN cells and endothelial cells, all of which may be relevant in the pathogenesis of advanced SM. Based on these observations DCC-2618 is a novel emerging drug candidate for advanced SM. Indeed, clinical trials with DCC-2618 have been started recently.

The multi-kinase inhibitor midostaurin (PKC412) is effective against the D816V-mutated variant of KIT and has shown promising results in patients with advanced SM in a global phase II trial, with an overall response rate of 60%. In addition, midostaurin was found to suppress mediator-related symptoms and IgE-dependent histamine release from basophils. However, despite clinical effi-

---

**Figures 4. Effects of DCC-2618 on anti-IgE-induced histamine release from normal basophils.** (A) Primary blood basophils from healthy donors were incubated in control medium (0 µM) or in various concentrations of DCC-2618, as indicated, at 37°C for 30 min. Thereafter, cells were incubated in control buffer or in buffer containing anti-IgE antibody E-124.2.8 (1 µg/mL) at 37°C for 30 min. After incubation, cells were centrifuged at 4°C, and cell-free supernatants and cell suspensions recovered and examined for histamine-content by radiomunnoassay. Histamine release was calculated as percent of total histamine and is expressed as percent of control. Results represent the mean±S.D. of four independent experiments. Asterisk (*): P<0.05 compared to control medium. (B) HMC-1.1 cells were cultured in the presence or absence of DCC-2618 (HMC-1.1: 25 nM; HMC-1.2: 500 nM) over a 6-day period. Spontaneous release of tryptase from HMC-1.1 and HMC-1.2 cells was measured by determining tryptase concentrations in cell-free supernatants and lysates. Tryptase release is expressed as percent of total (intra- and extra-cellular) tryptase. Results represent the mean±S.D. of three independent experiments. Asterisk (*): P<0.05.
Figures S. Effects of DCC-2618 and DP-5439 on proliferation and survival of acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). (A,C) MOLM-13, MV4-11, KG-1, U937 and primary leukemic cells were incubated in control medium (0 μM) or medium containing various concentrations of DCC-2618 or DP-5439, as indicated at 37°C for 48 h. Thereafter, 3H-thymidine uptake was determined. Results in (A) are expressed as percent of control and represent the mean±S.D. from three independent experiments. Asterisk (*): P<0.05 compared to control medium. Results of (C) are expressed as percent of control and represent the mean±S.D. from triplicates. (B) MOLM-13, MV4-11, KG-1 and U937 cells were incubated with control medium (0 nM) or various concentrations of DCC-2618 and DP-5439, as indicated, for 48 h. Thereafter cells were harvested and the percentage of apoptotic cells was quantified morphologically on Wright-Giemsa-stained cytospin preparations (left panels) or by flow cytometry (determination of annexin V/PI-positive cells, right panels). Results represent the mean±S.D. of three independent experiments. Asterisk (*): P<0.05 compared to control medium.
DCC-2618 is a new drug against mastocytosis

Inhibiting growth of primary eosinophils obtained from patients with KIT D816V-positive SM or reactive hypereosinophilia. Together, these data suggest that DCC-2618 inhibits multiple AHN-related cell types, which may be relevant clinically as progression of SM is often accompanied by multilineage expansion of various sub-clones, including cells harboring or lacking KIT D816V.

A number of different pro-angiogenic pathways and targets may be involved in KIT D816V-dependent expansion and accumulation of MC in advanced SM.23,40,44,45 Several of these target pathways may be sensitive to therapy with tyrosine kinase inhibitors. We studied whether key target pathways in neoplastic MC can be disrupted by DCC-2618. As assessed by Western blotting, DCC-2618 was found to block the phosphorylation and thus activation of wild-type KIT and KIT D816V. In addition, we were able to show that DCC-2618 blocks the activation of AKT, ERK and STAT5, suggesting that multiple target pathways are accessible to this drug. By contrast, however, the drug did not disrupt activation of BTK, another important target displayed by neoplastic MC.46

Since the target spectrum of midostaurin (PKC412) and DCC-2618 is not identical, we were also interested to learn whether DCC-2618 and midostaurin can produce synergistic antineoplastic effects on neoplastic MC. Indeed, we found that both drugs induce cooperative or even synergistic growth-inhibitory effects on HMC-1.1 and HMC-1.2 cells.

Specific alterations in the microenvironment, including increased angiogenesis, are frequently detectable in advanced bone marrow neoplasms and are often considered to play an important role in disease progression. A typical finding in the affected bone marrow of patients with advanced SM is increased microvessel density.27 We found that DCC-2618 inhibits the proliferation of human endothelial cells, including HUVEC and a microvascular endothelial cell line, HMEC-1. These data suggest that DCC-2618 also acts as an anti-angiogenic agent. Interestingly, the IC_{50} values obtained for HMEC-1 cells were higher than those for HUVEC, which may be explained by the fact that HMEC-1 is a cell line, whereas HUVEC are primary cells. An alternative explanation would be the lack of key targets in HMEC-1 cells. Indeed, it is well known, that KDR, a key target of DCC-2618, is only expressed in HUVEC but not in HMEC-1 cells.

Patients with SM frequently suffer from symptoms produced by MC-derived mediators.44-46 These mediators are released on IgE-dependent activation of MC and may cause severe problems or even lead to life-threatening anaphylaxis. Concomitant (IgE-dependent) allergies are, therefore, relevant comorbidities in the context of SM. We found that DCC-2618 counters IgE-dependent secretion of histamine from basophils obtained from healthy donors. In addition, we were able to show that DCC-2618 blocks IgE-independent, spontaneous release of tryptase from HMC-1.1 and HMC-1.2 cells in vitro. These results suggest that, apart from its antineoplastic effects, DCC-2618 might also have an impact on mediator release (and probably on the resulting symptoms) in patients with SM with concomitant allergies. Whether these data can be reproduced in vivo and whether the drug is able to suppress mediator symptoms in patients with advanced SM or SM with concomitant allergies remains to be determined. In fact, whereas the concentrations of

cacy, midostaurin is unable to produce long-lasting complete remission in all patients.24 Therefore, new drugs and drug-combinations are currently being tested in the context of advanced SM. DCC-2618 might be a promising candidate for several reasons. First, DCC-2618 exhibits a broad target profile and is able to block growth of various neoplastic cells.36 In the current study, DCC-2618 was found to block growth of neoplastic cells obtained from patients with ASM and MCL. In addition, the drug produced growth inhibition in all MCL-like cell lines tested, including KIT-mutated cells and cell lines in which other oncogenic pathways (such as the RAS pathway) trigger malignant cell growth. Moreover, unlike other KIT-targeting drugs, DCC-2618 is able to suppress the growth and survival of other cell types relevant to advanced SM and AHN, including monocytes, blast cells, neoplastic eosinophils and endothelial cells. The concentrations required to mediate these cellular inhibitory effects are readily achievable based on the recent report of clinical exposure of 5 μM or higher in patients with gastrointestinal stroma tumors.45

After intake, DCC-2618 is considered to be converted to one active metabolite, DP-5439. We therefore investigated whether DP-5439 is also able to counteract growth and survival of neoplastic cells. In these experiments, we were able to show that DP-5439 is able to suppress growth and survival of neoplastic MC and of other leukemic (non-MC-lineage) cells in the same way (and with comparable IC_{50} values) as DCC-2618. These data suggest that DCC-2618 treatment should be effective even if the DP-5439 metabolite may accumulate over time.

It is well known that about one-third of all patients with advanced SM have an AHN at diagnosis. Of these patients, most have a myeloid neoplasm, often in the form of CMMML or AML.2-8,13,32 The treatment of these SM-patients, most have a myeloid neoplasm, often in the advanced SM or SM with concomitant allergies remains to be determined. In fact, whereas the concentrations of
DCC-2618 required to block tryptase secretion in MC were rather low (<1.0 μM), the concentrations required to block IgE-dependent histamine release were rather high (1 μM).

Collectively, our data indicate that DCC-2618 is a novel promising agent that counteracts growth and survival of various cell types relevant to the pathogenesis of advanced SM. Whether DCC-2618 is able to block growth of neoplastic MC in patients with advanced SM is currently being explored in a clinical trial (NCT02571085).

Acknowledgments
This study was supported by a grant from Deciphera Pharmaceuticals LLC. We like to thank Dr. Dan Flynn, Dr. Bryan Smith and Dr. Oliver Rosen for helpful discussion.

References
1. Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol. 1991;96(3):25-45.
2. Valent P. Biology, classification and treatment of human mastocytosis. Wien Klin Wochenschr. 1996;108(15):385-397.
3. Horný HP, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res. 2001;25(7):543-551.
4. Escribano L, Akin C, Castells M, et al. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol. 2002;81(12):677-690.
5. Valent P, Akin C, Sperr WR, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol. 2003;122(5):695-717.
6. Akin C, Metcalfe DD. Systemic mastocytosis. Ann Rev Med. 2004;55:419-422.
7. Arock M, Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol. 2010;3(4):497-516.
8. Valent P, Horný H-P, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25(7):603-625.
9. Valent P, Horny H-P, Li CY, et al. Mastocytosis (mast cell disease). World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Eds: Harris NL, Stein H, Vardiman JW 2001;1:291-302.
10. Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129(1):1420-1427.
11. Horný HP, Akin C, Arber D, et al. Mastocytosis. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Eds: Swerdlow SH, Campo E, Harris NL et al. IARC Press Lyon, France, vol 3, pp 62-69, 2017;2:62-69.
12. Lim KH, Telferi A, Lasho TL, et al. Systemic mastocytosis in 542 consecutive adults: survival studies and prognostic factors. Blood. 2009;113(23):5727-5736.
13. Pardanani A, Lim KH, Lasho TL, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009;114(18):3769-3772.
14. Escribano L, Alvarez-Twose I, Sánchez-Muñoz L, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol. 2009;124(3):514-521.
15. Valent P, Akin C, Sperr WR, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res. 2015;37(7):635-641.
16. Arock M, Akin C, Hermine O, et al. Current treatment options in patients with mastocytosis: status in 2015 and future perspectives. Eur J Haematol. 2015;94(6):474-490.
17. Furtuiu T, Tumino R, Tomo T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of the c-kit product. J Clin Invest. 1995;92(4):1756-1744.
18. Nagata H, Horobec AS, Oh CK, et al. Identification of a point mutation in the c-tyrosine domain of the proto-oncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci. 1995;92(23):10560-10564.
19. Feger F, Strasser-Edwards S, Dikta G, et al. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol. 2002;127(2):110-114.
20. Longley BJ, Tynell E, Lu SZ, et al. Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet. 1996;12(5):512-514.
21. Fritsche-Bowmann K, Bäuerle A, et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol. 2001;113(2):357-360.
22. Arock M, Sperr WR, Dikta G, et al. Kit mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia. 2015;29(8):1225-1232.
23. Shah NE, Lee FY, Luo R, et al. Dasatinib (BMS-585428) inhibits KIT/D816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006;108(1):286-291.
24. Akin C, Brockow K, D’Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutant KIT. Blood. 2000;96(1):883-885.
25. Feger F, Strasser-Edwards S, Dikta G, et al. Kit mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia. 2015;29(8):1225-1232.
26. Shah NE, Lee FY, Luo R, et al. Dasatinib (BMS-585428) inhibits KIT/D816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006;108(1):286-291.
27. Akin C, Brockow K, D’Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutant KIT. Blood. 2000;96(1):883-885.
28. Arock M, Sperr WR, Dikta G, et al. Kit mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia. 2015;29(8):1225-1232.
29. Shah NE, Lee FY, Luo R, et al. Dasatinib (BMS-585428) inhibits KIT/D816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006;108(1):286-291.
30. Akin C, Brockow K, D’Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutant KIT. Blood. 2000;96(1):883-885.
31. Arock M, Sperr WR, Dikta G, et al. Kit mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia. 2015;29(8):1225-1232.
32. Arock M, Sperr WR, Dikta G, et al. Kit mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia. 2015;29(8):1225-1232.
33. Shah NE, Lee FY, Luo R, et al. Dasatinib (BMS-585428) inhibits KIT/D816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006;108(1):286-291.
34. Arock M, Sperr WR, Dikta G, et al. Kit mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia. 2015;29(8):1225-1232.
35. Smith BD, Hood MM, Wise SC, et al. DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models. Cancer Res. 2015;75(15): abstract 2690.
36. Bai Y, Bandara G, Ching Chan E, et al. Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation. Leukemia. 2015;27(2):278-285.
37. Butterfield JH, Weiiler D, Dewald G, Gleisch GJ. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res. 1985;12(4):345-355.
38. Saleh R, Weddell G, Haymanns H, et al. A new human mast cell line expressing a functional IgE receptor converts to factor-independence and tumorigenicity by KIT D816V-transfection. Blood. 2014;124(1):111-120.
39. Hoermann G, Blatt K, Greiner G, et al. CD52 is a molecular target in advanced systemic mastocytosis. FASEB J. 2014;28(2):
3540-3551.
40. Peter B, Gleixner KV, Cerny-Reiterer S, et al. Polo-like kinase-1 as novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of siRNA and the Polo-like kinase-1 targeting drug BI 2536. Haematologica. 2011;96(5):672-680.
41. Wimazal F, Jordan JH, Sperr WR, et al. Increased angiogenesis in the bone marrow of patients with systemic mastocytosis. Am J Pathol. 2002;160(5):1639-1645.
42. Peter B, Winter GE, Blatt K, et al. Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth. Leukemia. 2016;30(2):464-472.
43. Janku F, Razak ARA, Gordon MS, et al. Pharmacokinetic-driven phase I study of DCC-2618, a pan-KIT and PDGFRA inhibitor, in patients with gastrointestinal stroma tumor (GIST) and other solid tumors. J Clin Oncol. 2017;35(5):2515.
44. Ustun C, Arack M, Klein-Nelemans HC, et al. Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. Haematologica. 2016;101(10):1138-1143.
45. Jawhar M, Schwaab J, Schnitterg S, et al. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. Leukemia. 2016;30(1):136-143.
46. Gleixner KV, Mayerhofer M, Cerny-Reiterer S, et al. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and BTK activation and disruption by dasatinib and bosutinib. Blood. 2011;118(7):1885-1898.
47. Wilson TM, Maric I, Simakova O, et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica. 2011;96(5):459-463.
48. Schwaab J, Schnitterg S, Sotlar K, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013;122(14):2460-2466.
49. Bibi S, Langenfeld F, Jeanningros S, et al. Molecular defects in mastocytosis: KIT and beyond KIT. Immunol Allergy Clin North Am. 2014;34(2):259-262.
50. Damaj G, Joris M, Chandesris O, et al., ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS One. 2014;9(1):e85562.